Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review
Background. Tofacitinib is a new oral Janus kinase inhibitor that has shown promising clinical benefit in various rheumatologic diseases. However, many concerns related to the development of malignancies have been reported with its use. Case Presentation. A 43-year-old female patient received tofaci...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2019/2814504 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566819612786688 |
|---|---|
| author | Georgio Medawar Joseph Chahrouri Rabih Said |
| author_facet | Georgio Medawar Joseph Chahrouri Rabih Said |
| author_sort | Georgio Medawar |
| collection | DOAJ |
| description | Background. Tofacitinib is a new oral Janus kinase inhibitor that has shown promising clinical benefit in various rheumatologic diseases. However, many concerns related to the development of malignancies have been reported with its use. Case Presentation. A 43-year-old female patient received tofacitinib for refractory rheumatoid arthritis (RA). Two years after 5 mg bid daily dosing, the patient developed chronic myelogenous leukemia (CML), for which she received imatinib and tofacitinib was discontinued. She then remained in remission for rheumatoid arthritis and within the expected milestone outcome for her CML. Conclusion. This is the first reported case of CML after the use of tofacitinib. This event is of particular interest knowing the possible benefits tofacitinib carries in the treatment of CML demonstrated in a few studies. |
| format | Article |
| id | doaj-art-61eba896ab814a65a382a256512bf606 |
| institution | Kabale University |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-61eba896ab814a65a382a256512bf6062025-02-03T01:03:10ZengWileyCase Reports in Rheumatology2090-68892090-68972019-01-01201910.1155/2019/28145042814504Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature ReviewGeorgio Medawar0Joseph Chahrouri1Rabih Said2Internal Medicine Department, St George Hospital University Medical Center and the University of Balamand, Beirut, LebanonInternal Medicine Department, St George Hospital University Medical Center and the University of Balamand, Beirut, LebanonInternal Medicine Department, St George Hospital University Medical Center and the University of Balamand, Beirut, LebanonBackground. Tofacitinib is a new oral Janus kinase inhibitor that has shown promising clinical benefit in various rheumatologic diseases. However, many concerns related to the development of malignancies have been reported with its use. Case Presentation. A 43-year-old female patient received tofacitinib for refractory rheumatoid arthritis (RA). Two years after 5 mg bid daily dosing, the patient developed chronic myelogenous leukemia (CML), for which she received imatinib and tofacitinib was discontinued. She then remained in remission for rheumatoid arthritis and within the expected milestone outcome for her CML. Conclusion. This is the first reported case of CML after the use of tofacitinib. This event is of particular interest knowing the possible benefits tofacitinib carries in the treatment of CML demonstrated in a few studies.http://dx.doi.org/10.1155/2019/2814504 |
| spellingShingle | Georgio Medawar Joseph Chahrouri Rabih Said Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review Case Reports in Rheumatology |
| title | Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review |
| title_full | Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review |
| title_fullStr | Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review |
| title_full_unstemmed | Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review |
| title_short | Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review |
| title_sort | chronic myeloid leukemia in a patient receiving tofacitinib a case report and literature review |
| url | http://dx.doi.org/10.1155/2019/2814504 |
| work_keys_str_mv | AT georgiomedawar chronicmyeloidleukemiainapatientreceivingtofacitinibacasereportandliteraturereview AT josephchahrouri chronicmyeloidleukemiainapatientreceivingtofacitinibacasereportandliteraturereview AT rabihsaid chronicmyeloidleukemiainapatientreceivingtofacitinibacasereportandliteraturereview |